Vokes E E, Weichselbaum R R, Mick R, McEvilly J M, Haraf D J, Panje W R
Department of Medicine, University of Chicago Pritzker School of Medicine, IL.
J Natl Cancer Inst. 1992 Jun 3;84(11):877-82. doi: 10.1093/jnci/84.11.877.
The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy.
Our purpose was to administer induction chemotherapy, perform surgery, and administer concomitant chemoradiotherapy in rapid sequence and to evaluate their impact on locoregional and distant tumor control.
Sixty-four patients with previously untreated, locoregionally advanced head and neck cancer received two cycles of cisplatin, bleomycin, and methotrexate (PBM) (33 patients) or cisplatin, fluorouracil (5-FU), and leucovorin (PFL) (31 patients). PFL was given to patients who were unable to receive bleomycin. Local therapy consisted of surgery and/or concomitant chemoradiotherapy with 5-FU, hydroxyurea, leucovorin, and radiotherapy (FHX-L), all administered every other week.
Complete and overall induction response rates were 21% and 79%, respectively, for PBM and 29% and 81%, respectively, for PFL. At completion of local therapy, 81% of the patients were disease-free. With a median follow-up of 35 months, the median survival and time to progression are 22 and 17 months, respectively, for PBM and have not been reached for PFL. Locoregional recurrence of disease is 30% for PBM and 26% for PFL. Distant disease progression is 24% for PBM and only 3% for PFL.
The sequencing of induction chemotherapy and concomitant chemoradiotherapy is feasible and results in a high local control rate and in an encouraging survival rate with PFL. The high distant failure (i.e., outside the head and neck area) rate of PBM suggests insufficient systemic activity for that regimen.
Concomitant FHX-L chemoradiotherapy may improve regional control rates of advanced head and neck cancer. Effective systemic therapy may be needed to control systemic micrometastases. PFL, but not PBM, appears to be suitable to accomplish that goal.
大多数头颈癌患者死于手术和/或放疗后疾病的局部区域复发。
我们的目的是快速序贯给予诱导化疗、进行手术并给予同步放化疗,并评估它们对局部区域和远处肿瘤控制的影响。
64例先前未接受治疗、局部区域晚期头颈癌患者接受了两个周期的顺铂、博来霉素和甲氨蝶呤(PBM)(33例患者)或顺铂、氟尿嘧啶(5-FU)和亚叶酸钙(PFL)(31例患者)。无法接受博来霉素的患者给予PFL。局部治疗包括手术和/或同步放化疗,使用5-FU、羟基脲、亚叶酸钙和放疗(FHX-L),均每隔一周进行一次。
PBM组的完全缓解率和总诱导缓解率分别为21%和79%,PFL组分别为29%和81%。局部治疗结束时,81%的患者无疾病。中位随访35个月,PBM组的中位生存期和进展时间分别为22个月和17个月,PFL组尚未达到。PBM组疾病的局部区域复发率为30%,PFL组为26%。远处疾病进展率PBM组为24%,PFL组仅为3%。
诱导化疗和同步放化疗的序贯治疗是可行的,PFL方案可实现较高的局部控制率和令人鼓舞的生存率。PBM的高远处失败(即头颈部以外区域)率表明该方案的全身活性不足。
同步FHX-L放化疗可能提高晚期头颈癌的区域控制率。可能需要有效的全身治疗来控制全身微转移。PFL似乎适合实现这一目标,而PBM则不然。